Table 2 Distribution of somatic mutated genes and pathways by tumor site.

From: Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival

Subtype

Tumor site

Left-sided (n = 1184)

Right-sided (n = 899)

P valuea

MSI status

  MSI

47 (4%)

261 (29%)

2.77E−07

  MSS

1137 (96%)

638 (71%)

Hypermutation

  NHM

1088 (92%)

603 (67%)

0.467

  HM

96 (8%)

296 (33%)

Mutated genesb

 KRASc

 Mutated

379 (32%)

354 (39%)

7.79E−10

 Non-mutated

805 (68%)

545 (61%)

TP53d

 Mutated

759 (64%)

381 (42%)

1.98E−09

 Non-mutated

425 (36%)

518 (58%)

BRAFe

 Mutated

23 (2%)

132 (15%)

2.89E−05

 Non-mutated

1,161 (98%)

767 (85%)

BCL9

 Mutated

65 (5%)

68 (8%)

4.06E−05

 Non-mutated

1119 (95%)

831 (92%)

AMER1

 Mutated

57 (5%)

116 (13%)

1.10E−04

 Non-mutated

1,127 (95%)

783 (87%)

FBXW7

 Mutated

174 (14.7%)

135 (15%)

1.48E−04

 Non-mutated

1010 (85%)

764 (85%)

Mutated Pathwaysb

RTK/RAS

 Mutated

505 (43%)

586 (65%)

3.36E−12

 Non-mutated

679 (57%)

313 (35%)

TP53/ATM

 Mutated

789 (67%)

452 (50%)

9.62E−08

 Non-mutated

395 (33%)

447 (50%)

TGF-beta

 Mutated

246 (21%)

422 (47%)

3.85E−05

 Non-mutated

938 (79%)

477 (53%)

IGF2/PI-3-kinase

 Mutated

172 (15%)

271 (30%)

8.23E−05

 Non-mutated

1,012 (85%)

628 (70%)

  1. MSI microsatellite instability, MSS microsatellite stable, HM hypermutated, NHM non-hypermutated.
  2. aAnalyses adjusted for age at diagnosis, sex, mutation burden, MSI status and study. Significance threshold determined based on Bonferroni correction (205 genes, p value < 2.4 × 10−4, and 6 pathways, p value < 8.3 × 10−3.
  3. bGene and pathway mutation defined based on presence of non-silent mutations in genes.
  4. ccodons G12, G13, Q61, K117, and A146 mutations.
  5. dTranscript NM00546 encoding for the canonical p53 protein was used.
  6. eCodon V600 mutations.
Back to article page